Please ensure Javascript is enabled for purposes of website accessibility

Why Nevro Corp. Is Sinking Today

By Brian Feroldi - May 8, 2018 at 11:19AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares tumble after the company reports first-quarter results. Here's what investors need to know.

What happened

After reporting first-quarter results, shares in Nevro Corp. (NVRO 1.31%), a medical device maker that is focused on pain management, fell 15% as of 10:58 a.m. EDT on Tuesday.

So what

Here's a look at the headline numbers from the company's first quarter:

  • Revenue grew 28% to $87.6 million. The growth was driven by a 33% increase in North America and a 1% bump in currency-neutral sales in international markets. That result fell short of the $89.5 million in revenue that analysts had predicted.
  • Gross margin jumped 300 basis points to 71%. 
  • Operating expenses grew by 31% during the period, which outpaced revenue growth.
  • Net loss was $17.4 million, or $0.59 per share. That was much worse than the $0.32 loss per share that market watchers were expecting.
  • Management reaffirmed full-year revenue guidance of $400 million to $410 million.

Given the worse-than-expected results, it isn't hard to figure out why traders are in a foul mood today.

Business people looking upset in meeting.

Image source: Getty Images.

Now what

Nevro just recently won approval for its Senza II Spinal Cord Stimulation System in the U.S. and Europe so it is understandable that its expenses are growing rapidly as the company focuses on the launch. It costs a lot of money to market a medical device, especially when you are competing against well-funded industry giants like Boston Scientific and Medtronic, so I don't think that investors should be overly concerned with the larger-than-expected first-quarter loss.

However, I find Nevro's 1% sales growth in international markets to be a bit concerning, though I admit that it is possible that the recent approval of the Senza II is simply causing a delay in reorders. If true then it would explain why sales and net income came in far lower than expected this quarter.

Overall, I continue to see reasons for Nevro bulls to remain optimistic, especially with the company expected to flip to profitability in 2019. However, success with the Senza II is far from guaranteed, so investors need to brace themselves for a bumpy ride.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nevro Corp. Stock Quote
Nevro Corp.
$48.02 (1.31%) $0.62

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.